temoporfin Report issue

Small molecule Experimental
AACT ChEMBL Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Temoporfin (INN) is a photosensitizer used in photodynamic therapy for the treatment of squamous cell carcinoma of the head and neck . It is marketed in the European Union under the brand name Foscan. The U.S. Food and Drug Administration (FDA) declined to approve Foscan in 2000. The EU approved its use in June 2001.   Wikipedia

Chemistry

  • SMILES: Oc1cccc(c1)c2c3CCc(n3)c(c4cccc(O)c4)c5ccc([nH]5)c(c6C=Cc([nH]6)c(c7cccc(O)c7)c8ccc2n8)c9cccc(O)c9
  • InChIKey: KSXLETNRCMCRAQ-LWQDQPMZSA-N
  • Mol. Mass: 680.76
  • ALogP: 9.87
  • ChEMBL Molecule:
    temoporfin  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

5,10,15,20-tetra(m-hydroxyphenyl)chlorin | ef9 | foscan | fosgel | foslip | foslipos | meso-tetrahydroxyphenylchlorin | meso-tetra-(hydroxyphenyl)chlorin | meso-tetrahydroxyphenyl chlorin | mthpc | m-thpc | temoporfin

Organizations (14)

Research & Development (14)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (8)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (8)


 

Bile Duct Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Cholangiocarcinoma (Phase 2)

Head and Neck Neoplasms (Phase 2)

Klatskin Tumor (Phase 2)

Nasopharyngeal Carcinoma (Phase 2)

Neoplasms (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 8
  • # of Trial Organizations: 14

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue